Prevalence of Metabolic Syndrome in Patients With Psychotic Disorders in the Netherlands by Schorr, Susanne G. et al.
  
 University of Groningen
Prevalence of Metabolic Syndrome in Patients With Psychotic Disorders in the Netherlands
Schorr, Susanne G.; Slooff, Cees J.; Bruggeman, Richard; Taxis, Katja
Published in:
Journal of Clinical Psychopharmacology
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Schorr, S. G., Slooff, C. J., Bruggeman, R., & Taxis, K. (2009). Prevalence of Metabolic Syndrome in
Patients With Psychotic Disorders in the Netherlands. Journal of Clinical Psychopharmacology, 29(4), 399-
402.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019





We are replying to a Letter to theEditors that commented on our
article1 by Drs Chen et al.2 There were 2
primary study purposes in our article: the
ﬁrst one was to establish an early predic-
tion model for antipsychotic response in
schizophrenia; the second was to propose
an appropriate method to evaluate the
sensitivity, speciﬁcity and/or area under
curve values using a logistic regression
model (generalized estimating equation
method in our article1) in repeated mea-
surements study. In our article, we did
report that the predictive power for week 6
(0.82) was higher than that observed for
week 4 (0.80). This could be because of
the use of a pretty small cutoff point of
20% improvement on the Positive and
Negative Syndrome Scale, which ended
up at a higher response rate on week 6
(57%) than that on week 4 (51%).
However, comparing the results of ‘‘ﬁtted
models’’ and ‘‘simple models’’ in Table 2
of our article, we indicated that the
generalized estimating equation model
can get better prediction by incorporating
information on early response; otherwise,
the results of those 2 models were similar.
Also, in Table 2, the results of the Brief
Psychiatric Rating Scale simple model,
which used only the ﬁrst week response
status to predict the week 4 response, were
similar to the values reported by Correll
et al3 (high speciﬁcity and low sensitivity).
In Table 1 of their comments, which
had baseline characteristics ﬁxed at the
same values and varying response status
at week 1 or week 2, no difference in pre-
dicted response probabilities was ob-
served (Patients 198, 200; Table 1). This
is true for all model-based prediction
methods, not only for predicting response
probabilities (logistic regression model),
but also true for predicting Positive and
Negative Syndrome Scale total scores
(ﬁxed effects’ linear regression model).
The number of possible distinct predicted
values is exactly equal to the all possible
combinations of different values contained
in the independent variables (or predictive
variables) of the ﬁtted model. These phe-
nomena can easily be checked with small
sample size and with 1 or 2 independent
variables (better with categorical variables,
eg, sex) in the ﬁtted model.
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The association between neurolepticmalignant syndrome and risperi-
done treatment, although rare, is a well-
documented occurrence. Little has been
published, however, on the association
between clinical and laboratory markers
of acute pancreatitis and the use of ris-
peridone, although such evidence is of
some interest.1Y3 Acute pancreatitis caused
by risperidone is rare, but is characterized
by high mortality and morbidity rates,
as for any drug-induced pancreatitis,
where prompt detection of the causing
agent and its immediate suspension is
fundamental.1,2,4
Other studies on pancreatitis and the
use of atypical antipsychotics can be found
in the literature. These articles show that
there is a signiﬁcantly increased risk of
pancreatitis with the use of atypical anti-
psychotics as opposed to typical ones, such
as haloperidol.2
Evidence available in the literature
also shows that most cases of acute pan-
creatitis due to atypical antipsychotics
occur within six months of beginning
therapy.3 Here is a case of a biochemical
hyperamylasemia and hyperlipasemia, to-
gether with malignant neuroleptic syn-
drome (MNS), in a patient treated with
risperidone. The clinical features showed
up after 2 years of treatment.
CASE REPORT
A 45-year-old female, with a long-
term history of disorganized schizophre-
nia, was transferred to our clinic from the
internal medicine unit of the same hospi-
tal. A urinary catheter was placed, and she
was fed by nasogastric (NG) tube.
A month earlier, she had been
brought to the hospital by a family mem-
ber because she had developed muscular
stiffness, nonspeaking increased, opposi-
tivity, and food phobia; voluntary bowel or
urinary function had ceased, and a rise in
body temperature was noted.
Such clinical features were ac-
companied by a laboratory ﬁnding of hyper-
amylasemia, hyperlipasemia, myoglobinuria,
and an increase in creatine phosphoki-
nase (CPK) blood level. At this point
in time, besides the raised temperature
and reduced motility, there were signs of
rhabdomyolysis (liver and kidney func-
tions still being intact) and probable acute
pancreatitis.
For this reason, an NG tube and
bladder catheter were positioned; an ab-
dominal computed tomography scan was
carried out and showed no signiﬁcant ﬁnd-
ing and the previously mentioned bio-
chemical markers were checked daily.
During the following days, al-
though myoglobinuria and CPK were
progressively reduced to normal levels,
amylasemia and lipasemia increased up to
a maximum level of 636 U/L (normal
range, 5Y53 U/L) and 1293 U/L (114Y286
U/L), respectively, despite the absence of
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any clinical or radiological evidence. A
ﬂuctuating temperature was still present.
Because the situation did not re-
quire any emergency or short-term med-
ical or surgical intervention, the patient
was transferred to our clinic.
During the ﬁrst days of her stay,
she was almost inaccessible to interview,
laconic, oppositive, and negativistic, with
an overall muscular stiffness and adyna-
mia. She was awake, not very lucid and,
apart from the lack of cooperation, she
seemed to be oriented toward people but
partly confused toward time and space.
Somatic examination was negative.
Neurological examination showed an ex-
trapyramidal stiffness, increased by the
oppositivism of the patient. From a
general clinical point of view, there was
still a moderate increase in temperature,
with remittent proﬁle. Blood pressure was
stable, within normal range; CPK and
rhabdomyolysis marker, myoglobinuria,
were already within normal range when
the patient was transferred to our unit.
Amylase and lipase were still high (around
the highest level shown above).
The patient was fed for several days
through NG tube, the urinary catheter was
kept in place and anticoagulant prophy-
laxis was provided, with low molecular
weight heparin subcutaneously.
From the pharmacological point of
view, we decided to suspend risperidone,
which the patient had been taking for the
previous 2 years. We then introduced a
therapy based on intravenously loraze-
pam, in 250 cc saline solution, 3 times a
day, converted into an intramuscular
preparation, which produced a slow but
progressive solution to the muscular
stiffness. This conﬁrmed our hypothesis
that such a clinical feature was primarily
due to MNS from risperidone, rather than
being caused by psychopathological syn-
drome (which, in this latter case, would
have been schizophrenia, catatonic type).
The values of amylasemia and
lipasemia were progressively reduced,
returning within normal range in 20 days.
This ﬁnding suggested a cause-effect rela-
tionship between the use of risperidone
and the biochemical features of acute pan-
creatitis. Radiological examinations (com-
puted tomography scan performed in the
internal medicine unit, ultrasound per-
formed during admission into our unit),
not showing any morphological sign of
pancreatitis, suggest an edematous form of
pancreatitis, probably already recovering at
that time, as imaging produced no signif-
icant ﬁnding. The literature already shows
evidence of asymptomatic pancreatitis
related to another atypical antipsychotic
agent, clozapine.5
The NG tube was removed at this
point, and the patient went back to oral
nutrition, beginning with a diet based on
easy to swallow food; she also began to be
mobilized.
The urinary catheter was removed,
bowel training with intermittent catheter-
ization was provided, and the patient was
promptly able to regain physiological
urination.
Once the general clinical conditions
and biochemical markers were stable, we
introduced clozapine into the treatment
plan, starting with 12.5 mg a day and
moving within little more than a month up
to 300 mg a day. Such treatment signiﬁ-
cantly improved the psychopathological
outcome, and the patient was discharged.
At an 18-month follow-up, the
patient still maintains a good clinical
balance; monthly blood tests, including
amylase and lipase and blood cell count,
mandatory with treatment with clozapine,
were negative.
This seems to suggest that the
susceptibility to pancreatic dysfunction
related to MNS induced by atypical anti-
psychotics is based on subjective factors,
in relation to the speciﬁc drug used in
treatment, risperidone in this case, rather
than to clozapine, which has had more
prominence up to now in the literature.3,5Y9
This case also shows that pancreatic dys-
function may occur even long after the
beginning of treatment with atypical anti-
psychotics. It might then be worth inves-
tigating further whether regular long-term
monitoring of pancreas function could
represent an effective tool for secondary
prevention. Early diagnosis and prompt in-
terruption of pharmacological treatment
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Inﬂammation-related alterations of drugpharmacokinetics in humans were for
the ﬁrst time published in 1978 by Chang
et al,1 who observed a signiﬁcantly im-
paired clearance of theophylline during
upper respiratory tract infections. The
antipsychotic drug clozapine (CLZ) is
liable to a very similar biotransformation
and elimination like theophylline.2 In the
last years, individual case reports were
published on patients who suffered se-
rious adverse effects due to an increase of
CLZ serum concentrations during acute
infections.3Y6 To further clarify the ques-
tion of an association between increased
CLZ serum levels and inﬂammations, we
evaluated retrospectively the relationship
between pathological values of the inﬂam-
matory biomarker C-reactive protein
(CRP) and increased CLZ serum levels.
We chose CRP as laboratory parameter for
an inﬂammatory process because it is the
prototypical acute phase serum protein,
rising rapidly in response to inﬂammation,
and is free of diurnal variations as well as
age or sex dependency.7
All therapeutic drug monitoring
(TDM) analyses of CLZ performed in the
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Clinic of Wu¨rzburg between 2004 and
2007 were retrospectively screened for
CLZ serum levels of more than 800 ng/
mL, which is clearly above the recom-
mended therapeutic range (350Y600 ng/
mL).8 Subsequently, we checked whether
CRP was determined parallel (T1 day)
to the TDM. A comparison group was
formed by extracting patients with CLZ
serum levels within the recommended
therapeutic range in whom CRP also had
been determined parallel to the CLZ con-
centration. Clozapine determinations in
the comparison group were conducted
within the same time period like in the
proband group. Both groups were
matched as far as possible with respect
to age and sex proportion. Patients older
than 65 years and patients receiving
drugs which are known as inhibitors of
the metabolic activity of CYP1A2 or
CYP3A4 were excluded in both groups.
The reasons for elevated CRP con-
cerned mostly respiratory or urinary tract
infection, but were not recorded sys-
tematically. The clinical consequences of
the elevated CLZ were also not captured
systematically. A relationship with other
laboratory parameters like >-1 acid gly-
coprotein was not examined.
The frequencies of abnormal CRP
values and the mean and median value of
CRP among the patients with elevated
CLZ serum levels and the patients with
serum levels within the therapeutically
recommended range were compared.
In total, 27 patients (9 male, 18 fe-
male) with an elevated CLZ serum level
and 36 patients (12 male, 24 female) with
a CLZ serum level within the recom-
mended range could be included. Regard-
ing mean age, mean body weight, sex
distribution, applied daily doses, and
percentage of smokers, there were no
signiﬁcant differences between both
groups. Data concerning CRP values are
displayed in Table 1. Patients with an
inﬂated CLZ level showed signiﬁcantly
more often an abnormal CRP value than
patients with a normal CLZ level. The
difference became even more apparent if
only markedly increased CRP values of
more than 1.0mg/dLwere considered. The
mean CRP value was signiﬁcantly higher
in the probands with elevated CLZ con-
centrations than in those with CLZ con-
centrations within the recommended
range. To determine the contribution of
the factors age, sex, body weight, dosage,
smoking habits, and CRP elevation
(91.0 mg/dL) on the probability of an
elevated serum level of CLZ, a binary
logistic regression was carried out. With
the stepwise forward entry approach, the
proposed model only contained CRP
elevation. The factors daily CLZ dosage,
age, sex, body weight, and smoking habits
were not relevant. The predictive proba-
bility for this model was 75.4% (W2 = 16.6;
df = 1; P G 0.001) after 1 step. Inclusion
of further factors did not improve the
differentiation.
DISCUSSION
We found in patients with an in-
creased CLZ serum level signiﬁcantly
more often a pathological CRP value and
a signiﬁcantly higher mean CRP value
than in patients with a normal CLZ level.
A binary logistic regression revealed CRP
elevation as the most relevant predictive
factor for an increase of the CLZ serum
level. Because we had excluded cases in
which any of the concomitant drugs had
a known potential for an inhibition of
CYP1A2 or CYP3A4, it is highly im-
probable that drug interactions are respon-
sible for the elevation of serum CLZ
concentration.
Elevated CLZ serum levels in con-
nection with an inﬂammatory reaction or
infection are described in several case
reports,3Y6 which are in accordance with
our ﬁndings.
The most obvious explanation for a
rise of the CLZ serum level would be a
reduction in the activity of the metaboliz-
ing enzymes. According to in vitro data,
acute infections or inﬂammations may
lead to a compromised drug metabolism
which involves various CYP450 subtypes
mostly via a down-regulation of their
activity mediated by reduced tran-
scription.9Y14 The activity of the speciﬁc
isoforms CYP3A4 and CYP1A2, which
are important in CLZ metabolism, can be
affected in this way.11,12 Several forms of
cytokines, namely interleukin 1A and IL6,
but also tumor necrosis factor > and
interferons > or F can mediate this
effect.11,12 There may also be other
mechanisms which can cause elevated
cytokine levels with a subsequent rise of
CLZ serum concentration via a cytokine-
mediated down-regulation of CYP450
enzymes. In some cases, CLZ itself may
be the cause of the inﬂammatory con-
dition by means of a CLZ-mediated
hypersensitivity reaction which results
in an increased release of inﬂammatory
cytokines.5
Altogether our ﬁndings suggest that
changes in laboratory parameters indicat-
ing an inﬂammatory reaction, especially a
rise of CRP, as well as clinical signs of an
incipient infection should be seen as suf-
ﬁcient reason to have serum CLZ concen-
trations determined by therapeutic drug
monitoring, as a dose reduction may be
required to prevent intoxication and side
effects in patients. Up to now, data re-
garding a possible impact of inﬂammatory
diseases on the biotransformation of other
psychotropic agents are nearly completely
lacking. Further studies are necessary to
address this important question.
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TABLE 1. CRP Values in Patients With Normal and Elevated CLZ Serum Levels
Normal CLZ Level
(350Y600 ng/mL), n = 36
(12 Males, 24 Females)
Elevated CLZ Level
(9800 ng/mL), n = 27
(9 Males, 18 Females) Statistics
N abnormal CRP values
(90.5 mg/dL)




3 (8%) 15 (56%) W2 = 16.858;
P G 0.001*
CRP, mg/dL
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Although the favorable side effect pro-ﬁle of aripiprazole1 could provide
long-term beneﬁts, switching to this med-
ication is not always successful in all
patients.2 Although this phenomenon is
seen in all available antipsychotics, differ-
ent mechanisms may be involved with
clinical worsening after a switch to
aripiprazole that exceptionally has a par-
tial agonistic activity at dopamine D2
receptors. Given the unique action of this
drug, it would be important to elucidate
the time course and predictors of the
worsening after the switch from a full
antagonist antipsychotic to aripiprazole,
which would be expected to help physi-
cians more effectively monitor patients
while acknowledging the importance of
careful monitoring in every patient. This
notwithstanding, there is no investigation
that tried to identify predictors of clinical
worsening after switching to aripiprazole.
We therefore conducted a 1-year follow-up
study to examine the time course and
potential predictors of clinical worsening
following a switch to aripiprazole in
patients with schizophrenia.
This 1-year naturalistic follow-up
study was conducted at 3 psychiatric
hospitals and clinics in Tokyo, Japan.
Consecutive inpatients and outpatients
aged 18 years and older, who met the
Diagnostic and Statistical Manual of
Mental Disorders Fourth Edition criteria
for schizophrenia and were treated with a
stabilized dose of oral antipsychotics for
at least 1 month before study entry, were
assessed for inclusion in the study, and all
eligible patients were approached to par-
ticipate in the study. The exclusion criteria
included the presence of Diagnostic and
Statistical Manual of Mental Disorders
Fourth Edition-deﬁned substance abuse
or dependence within the preceding 6
months, serious neurological or uncon-
trolled medical condition(s), and a treat-
ment history of clozapine.
Aripiprazole was initiated at 12 mg/d,
maintained at the same dose for the ﬁrst
2 weeks, and then titrated between 12 and
30 mg/d until week 52. Previous anti-
psychotics were reduced biweekly by
25%, whereas other psychotropics were
not changed throughout the study period.
Participants received monthly assess-
ments, using the Clinical Global Impres-
sion: severity of illness (CGI-S).3 Patients
who showed a 1 point or more increase in
the CGI-S within 1 year were classiﬁed as
‘‘worsened group’’ whereas the others
were deﬁned as ‘‘stabilized group’’. The
trial protocol was approved by the institu-
tional review board at each participating
site. After full description of the study, all
participants provided their written in-
formed consent before entering the study.
Demographic variables were com-
pared between the 2 groups by the Student
t test or the W2 test, as appropriate. Logistic
regression analysis was used to examine
predictors of worsening among age, sex,
treatment setting (ie, in/outpatient), dura-
tion of illness, previous antipsychotic
dose, aripiprazole dose, and baseline
CGI-S. Baseline antipsychotic doses
were converted to daily deﬁned dose
(DDD) unit4 or chlorpromazine equiva-
lents (CPZE) on the basis of a previous
report,5 in which relative potency of each
antipsychotic agent was determined based
on its clinical efﬁcacy in human clinical
trials. When they received 2 or more
antipsychotics, the sum of DDD or CPZE
was calculated. A 2-tailed P G 0.05 was
considered statistically signiﬁcant. Statis-
tical analyses were carried out, using the
Statistical Package for Social Science
version 16.0 for Windows (SPSS Inc,
Chicago, Ill).
Forty patients were enrolled; of these,
16 (40.0%) patients experienced a clinical
worsening within 1 year (Table 1). All
these worsened patients experienced exac-
erbation of auditory hallucination and/or
delusion. A mean T SD interval between
the switch and clinical worsening was
12.8 T 7.1 weeks (range, 4 to 34 weeks),
and it occurred within 17 weeks in more
than 90% of the patients (n = 15).
The dose of previous antipsychotics
was signiﬁcantly higher in the worsened
group than the stabilized group (Table 1).
In addition, when patients on risperidone
or olanzapine at baseline were separately
analyzed, those who experienced a clinical
worsening received higher doses (risper-
idone, mean T SD, 7.7 T 2.9 mg/d [n = 6]
vs 3.3 T 1.4 mg/d [n = 8] P G 0.01;
olanzapine, mean T SD, 14.4 T 5.3 mg/d
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[n = 9] vs 10.0 T 3.0 mg/d [n = 12], P G
0.05). No signiﬁcant differences were
found in other demographic and clinical
variables between the 2 groups. A logistic
regression analysis found that only a
higher dose of previous antipsychotics
before aripiprazole was associated with
clinical worsening (odds ratio, 1.02; 95%
conﬁdence interval, 1.00Y1.02; P G 0.05).
Among thoseworsened patients, 8 patients
were stabilized by a dose escalation (n =
6) or a careful course observation alone
(n = 2). In addition, when these 8 patients
were included in the stabilized group, the
difference in previous antipsychotic dose
between the 2 groups was found in terms of
both DDD unit (mean T SD, 1.71 T 0.68
vs 1.06 T 0.59;PG 0.01) andCPZE (mean T
SD, 725.0 T 307.1 mg/d vs 468.4 T
258.4 mg/d; P G 0.05).
DISCUSSION
A higher dose of previous antipsy-
chotic dose was found to be associated
with subsequent clinical worsening after
the switch to aripiprazole. One possibility
would be that patients who received a
higher dose might suffer more severe
symptomatology at baseline. Those po-
tentially more severe patients may be more
likely to fail to tolerate an antipsychotic
switch. However, this possibility could be
negated by the fact that no signiﬁcant
difference was found in terms of the
baseline CGI-S in the present study.
Alternatively, we suppose that a potential
difference in the dopamine receptor re-
serve needs to be considered. Administra-
tion of antipsychotic drugs has been
reported to lead to an elevation in
dopamine D2 receptors,
6 and the evidence
suggests that this up-regulation may be in
the range of 30% to 40%.6 If this up-
regulation could be dose-dependent,
patients who have been treated with a
higher dose of previous antipsychotics
would experience a greater increase in the
net dopaminergic transmission after
switching to a partial agonist, aripiprazole.
This in turn would be expected to result in
a clinical worsening. In any case, a more
careful observation should be given to
patients who receive a relatively high dose
of antipsychotics when a switch to ari-
piprazole is performed.
Out of the 16 worsened patients,
8 patients were stabilized by increasing
the dose of aripiprazole or a careful course
observation, which means that switching
to aripiprazole was not feasible in the
remaining 8 (20%) patients. This rate is
comparable to that in one retrospective
6-month cohort study in the US (n = 444)7
that showed 20% of outpatients switched
to aripiprazole were hospitalized within
6 months. This study also found that a
mean time to hospitalization after switch-
ing was 65.7 days in aripiprazole, similar
to the mean time to worsening of 13 weeks
in the present study. These observations
emphasized the need of a more thorough
monitoring within 3 months after switch-
ing to aripiprazole. This period may need
to be extended to 4 months because more
than 90% of worsened patients experi-
enced a clinical worsening within 17
weeks in this study.
Several limitations should be noted.
First, the small sample size limits the in-
terpretation of our results. Second, the
minimum duration of receiving stabilized
dose of antipsychotics (1 month) in the
inclusion criteria might be too short,
which might have included heterogeneous
patients. Third, psychopharmacological
management for worsened patients was
not standardized. Fourth, psychopathol-
ogy was assessed, using the CGI alone, in
this study. Our primary interest was to
identify predictors of clinical worsening
after switching to aripiprazone in the real-
world clinical setting. Although it would
have been ideal to perform comprehensive
assessments, practical clinical issues
limit the extent to which they can be
applied in busy clinical practice. Still,
taken together with the open-label study
design with a small sample size of this
study, more methodologically sound stud-
ies, using structured comprehensive assess-
ments, in larger samples are needed to
better understand predictors of clinical
worsening.
In conclusion, the ﬁndings of this
study suggest that patients who receive a
relatively high dose of antipsychotics may
have a greater risk of clinical worsening
after a switch to aripiprazole and require a
more thorough observation within the ﬁrst
4 months. This has important clinical
implications, both in terms of providing
safe antipsychotic treatment and under-
standing potential mechanisms of psy-
chotic decompensation after a switch from
a full antagonist antipsychotic to a partial
agonist antipsychotic.
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Male, n (%) 15 (62.5) 7 (43.8)
Inpatient, n (%) 13 (54.2) 9 (56.3)
Age, y 53.0 T 16.6 55.3 T 16.8
Duration of illness, y 23.9 T 17.5 28.9 T 18.3
Previous antipsychotic dose
DDD, unit 0.87 T 0.35 1.66 T 0.72†
CPZE, mg/d 381.8 T 155.5 726.6 T 311.4†
Concomitant use of benzodiazepines, n (%) 12 (50.0) 10 (62.5)
Baseline CGI-S 4.1 T 1.1 4.6 T 1.0
Aripiprazole dose, mg/d 16.8 T 3.1 18.0 T 0.0
Values are shown as mean T SD.
*There were no signiﬁcant differences in all clinical variables except for previous antipsychotic
dose between the 2 groups by the Student t test or the W2 test.
†P G 0.05 by the Student t test.
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Cognitive dysfunction is a core featureof schizophrenia and is present in
most patients with the illness, frequently
preceding the onset of other symptoms
and persisting even after other symptoms
have been effectively treated.1 These
abnormalities, which are the best predictor
of impairments in various aspects of
functional outcome in schizophrenia,2,3
predict poorer treatment adherence4,5 and
increased tendency for relapse in ﬁrst epi-
sode patients.6
Several of the cognitive deﬁcits
found in patients with schizophrenia are
also present in individuals with other
schizophrenia spectrum disorders, such as
schizotypal personality disorder (SPD).7Y10
We have previously demonstrated that
the cognitive impairments of individuals
with SPD are amenable to treatment with
pharmacological agents, in particular
those that modulate catecholamine func-
tioning. In particular, 4 weeks of treatment
with guanfacine, signiﬁcantly improved
the context processing abilities of SPD
participants compared with those treated
with placebo.11 In addition, treatment of
SPD patients with a low dose of ris-
peridone resulted in a signiﬁcant reduc-
tion in negative and general symptoms over
3 weeks.12
There is some evidence that second
generation, or atypical antipsychotics, im-
prove the cognitive performance of indi-
viduals with schizophrenia.13,14 Based on
these results, we sought to evaluate the
impact of risperidone on the cognitive
functioning of individuals with SPD. We
hypothesized that risperidone would re-
sult in improvements in the cognitive per-
formance of SPD participants, in that
guanfacine was more effective at reducing
cognitive impairments in people with SPD
than in schizophrenia.11,15
We recruited male or female partici-
pants between the ages of 18 and 60 years
from the outpatient clinics at the Mount
Sinai Medical Center (New York, NY) and
the Bronx Veterans Affairs Medical Cen-
ter (Bronx, NY). Participants were re-
quired to meet Diagnostic and Statistical
Manual of Mental Disorders-Fourth Edi-
tion criteria for SPD. When there was
comorbidity with other personality dis-
orders, SPD was judged by to be the pri-
mary diagnosis. All patients received a
urine toxicology screen. See our previous
publications for the full diagnostic assess-
ment. The study was approved by the
institutional review boards at the 2 institu-
tions, and all participants signed a written
informed consent statement. Data were
collected from 1995 to 2001.
Patients were randomly assigned in a
1:1 ratio to receive risperidone or placebo
in identical tablets. All patients received
a single-blind 2-week placebo lead-in fol-
lowed by a double-blind 10-week medi-
cation trial. The dosage of risperidone
was titrated upward in a stepwise de-
sign, beginning with 0.25 mg/d for the
ﬁrst week, 0.5 mg/d for weeks 2 and 3,
1.0 mg/d for weeks 4 and 5, 1.5 mg/d for
weeks 6 and 7, and 2.0 mg/d for the
remaining weeks. Cognitive performance
was assessed at baseline, as well as at
weeks 6 and 12. The cognitive assessment
battery consisted of measures of a range
of neuropsychological functions, includ-
ing spatial and verbal working memory,
vigilance, spatial memory, and word list
learning (for a more complete description
of these assessments, please see our
previous work7). For all the dependent va-
riables, we computed change scores from
baseline to 6 and 12 weeks. We then con-
ducted a series of univariate analyses of
variance comparing the change scores of
individuals in our risperidone group to
those in our placebo group.
Thirty-one participants entered into
the study, 19 of whom were randomized
to risperidone and 12 to placebo. Several
participants in both groups dropped out
of the study for various reasons, such as
boredom or fatigue, ostensibly not related
to group assignment. Two participants in
the risperidone group were withdrawn, 1
because of an increase in suicidal ideation
and 1 because of galactorrhea. In total,
9 participants in the placebo group and
11 participants in the risperidone group
completed all 12 weeks of the trial and
were included in the analysis. The groups
did not differ signiﬁcantly in the number
of participants who terminated premature-
ly (Fisher exact test, P = 0.452, NS). The
groups were also comparable in terms of
age, education, sex, vocabulary scores, or
block design performance (all Ps = NS).
Clinical response to risperidone was
previously reported12 in a sample that
included 23 of the 31 participants in the
current study; raw scores on the symptom
assessment of the current sample are
presented in Table 1.
Raw scores for the cognitive assess-
ments at baseline, week 6 and week 12,
are presented in Table 1. There were no
signiﬁcant differences between the ris-
peridone group and the placebo group in
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change from baseline on any of the cog-
nitive variables following either 6 weeks,
all Fs G 2.5, all Ps 9 0.15, or 12 weeks,
all Fs G 1.2, all Ps 9 0.28, of treatment.
DISCUSSION
We hypothesized that individuals
with SPD, who frequently demonstrate a
similar proﬁle of cognitive impairment to
individuals with schizophrenia, would be-
neﬁt from treatment with risperidone, as
they had previously been shown to beneﬁt
from other cognitive enhancement thera-
pies. The results of the current study did
not support this hypothesis and are not
as large as those seen in the generally
negative Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) trial
looking at schizophrenia patients and
atypical antipsychotics.16 These data sug-
gest that although antipsychotic medica-
tionsmay reduce clinical symptoms inSPD,
they may not have a substantial beneﬁt for
cognitive functioning.
There are several possible explana-
tions for our failure to ﬁnd statistically sig-
niﬁcant results. The small sample size and
high number of drop-outs led to modest
power. Furthermore, examination of base-
line performance in both groups suggests
that the SPD patients were less impaired on
cognitive measures than cohorts in our
previous studies. Although we failed to ﬁnd
statistically signiﬁcant differences between
individuals with SPD treated with risper-
idone and those treated with placebo on our
cognitive assessments, more severe cogni-
tive impairment in SPDmight have respon-
ded to risperidone. Future research on other
treatments targeting these deﬁcits in SPD
is warranted, especially in those individuals
who demonstrate cognitive abnormalities
that are closer to the severity of what is
seen in schizophrenia.
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The treatment of refractory psychotic ormood disorders often requires combi-
national drug therapy. We report here on a
patient with refractory schizoaffective dis-
order, who presented with rhabdomyolysis
after a dose increase of clozapine and com-
bination therapy with lithium.
CASE REPORT
Mr A, a 29-year-old Taiwanese
man, was initially diagnosed with bipolar
disorder at age 16 years. Because of poor
control of his mood symptoms and the de-
velopment of auditory hallucinations, he
had been tried on many medications, in-
cluding carbamazepine, haloperidol, risper-
idone, and olanzapine. At age 26 years, he
was readmitted because of symptoms of
schizophrenia. A variety of medications,
including ziprasidone, amisulpride, and
olanzapine, were then tried but without
adequate efﬁcacy. Finally, he was pre-
scribed clozapine (125Y200 mg/d).
At age 29 years, he was re-hospi-
talized because of recurrent ﬂorid psy-
chotic and manic symptoms, and his
diagnosis was changed to schizoaffective
disorder. We gradually titrated the cloza-
pine dose up to 450mg/d over 5 weeks and
added valproic acid which was increased
to 2000 mg/d within a month (Table 1).
Although his psychotic symptoms im-
proved, his mood symptoms persisted
and thus, 8 sessions of electroconvulsive
therapy (ECT) were performed between
day 43 and day 68. Although improve-
ment was noted, his manic symptoms
recurred within 1 week after the end of
ECT. Clozapine was increased further to
500mg/d on day 72. Lithiumwas added on
day 78, and the dose was titrated to
1200 mg/d within a week. Manic symp-
toms showed partial improvement.
Generalized muscle aches were
noted on day 89 (17 days after the
clozapine dose increased to 500 mg/d),
and laboratory examination revealed in-
creased serum creatine kinase (CK 6776
IU/L). Rhabdomyolysis was the probable
diagnosis after excluding infection and
neuroleptic malignant syndrome. We re-
duced his clozapine dose from 500 mg/d
to 400 mg/d on day 90. After adequate
intravenous hydration, his physical symp-
toms and CK levels gradually returned to
normal within a week. He was discharged
on day 109.
DISCUSSION
Previous evidence that substance
abuse and medical drugs are 2 major
causes of rhabdomyolysis in hospitalized
patients prompted us to investigate the
adverse effects of the anti-psychosis med-
ications administered in this case.1 Rhab-
domyolysis had been documented in
case reports involving an overdose of
lithium,2Y4 clozapine,5 or valproic acid.6
Rhabdomyolysis cases have also been re-
ported in the process of correction of hy-
ponatremia associated with polydipsia and
clozapine use.7,8 Lithium-induced rhab-
domyolysis might be related to a hyper-
osmolar state,9 or polydipsia-induced
hyponatremia.10
Clozapine is a potent 5HT2a antago-
nist that might interact with serotonin,
leading to passive diffusion of serotonin
into skeletal muscle cells. The resultant
accumulation of serotonin can be toxic to
skeletal muscle cells, resulting in cell ne-
crosis and increased blood CK levels.11 In
this patient, a dose increase of clozapine
from 450 to 500 mg/d seemed on its own
could induce rhabdomyolysis, judging
from the fact that he tolerated clozapine
at a dose of 400 mg/d in combination with
lithium at a dose of 1200 mg/d after day
90. The role of lithium cannot be com-
pletely excluded because a combination
of both drugs might theoretically induce
pharmacokinetic or pharmacodynamic
changes. The interaction between lithium
and clozapine and the effect of their in-
teraction on rhabdomyolysis remain un-
clear. We speculate that the change in
serum osmolarity associated with lithium
might result in changes in the permeability
of cell membranes, especially those of
skeletal muscle. In this situation, the ad-
junct use of antipsychotics may cause in-
creased amounts of serotonin to diffuse
into cells, causing the breakdown of skele-
tal muscle. However, serum osmolarity,
sodium or potassium levels for this patient
were not obtained on the day when rhab-
domyolysis occurred, so we cannot rule
out other explanations.
To our knowledge, this is the ﬁrst
case report in which combined treatment
with clozapine and lithium appears to have
caused rhabdomyolysis in the absence
of a toxic serum level of lithium. Conse-
quently, in addition to monitoring se-
rum levels to maintain below-toxic levels
of medication(s), we suggest paying close
attention to patient reports of muscle
aches and, when necessary, regularly
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checking serum CK levels, serum osmo-
larity, and serum electrolytes, to monitor
for rhabdomyolysis during the treatment
of refractory psychotic or mood disorders.
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Patientswith chronic psychotic disordershave an elevated risk for developing
cardiovascular and metabolic diseases.1
The metabolic syndrome is a measure for
the clustering of metabolic and cardiovas-
cular risk factors and is frequently used
in patients with psychotic disorders.2,3 So
far, no study has been conducted to de-
scribe the prevalence of the metabolic
syndrome in patients with psychotic dis-
orders in theNetherlands. This study aimed
to estimate the prevalence of metabolic
syndrome and to compare characteristics
of patients with metabolic syndrome to
those without.
This cross-sectional analysis of pa-
tients with psychotic disorders participat-
ing in a disease management program was
conducted in the department of psychotic
disorders of a mental health care center
in the Netherlands between January 2003
and April 2007. As part of the disease
management program, patients had yearly
assessments of their somatic and psychi-
atric health. Patients with missing data of
criteria of the metabolic syndrome were
excluded from the analysis. The metabolic
syndrome was deﬁned by the criteria of
the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection,
TABLE 1. Summary of Treatment Course and Associated Laboratory Examinations
Days After Admission




300 350 450 450 450 450 450 500 500 500 500 500 500 400 400 400 400 400
Valproic acid
(mg/day)
1500 2000 2000 hold hold hold 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000
Lithium, mg/d 600 900 1200 1200 1200 1200 1200 1200 1200





84.9 89.3 98.24 47.94 82.85 75 84.2 77.55
Lithium,
mmol/L
0.27 0.64 0.48 0.41 0.45 0.83
WBC, K/KL 10.13 11.04 7.78 8.31 13.03 10.14 12.03 12.45 11.33
CK, IU/L 6776 3494 1261 222 147 97
BUN, mg/dL 9.8 7.1 6.2 7.3
Cre, mg/dL 1.1 0.9 1.0 1.2
WBC indicates white blood cell; BUN, blood urea nitrogen; Cre, creatinine; **, marks of ECT.
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Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment
Panel [ATP] III).4 Furthermore, we esti-
mated the prevalence of the metabolic
syndrome according to the deﬁnition of
the ATP IIIa (adapted version of the
ATP III)5 and the International Diabetes
Federation (IDF).6 When a fasting assess-
ment was not available, hyperglycemia
was deﬁned by HbA1c of more than
6.2% instead of glucose criterion of the
ATP III/NCEP (ATP IIIa, IDF: HbA1c
95.7%) and hypertriglyceridemia by tri-
glycerides of more than 2.2 mmol/L. We
conducted a subanalysis to estimate the
prevalence of the metabolic syndrome in
the cohort of patients with a measure of
fasting glucose. We used the Mann-
Whitney test and the W2 test to compare
the characteristics of the patients with
metabolic syndrome (ATP III/NCEP) to
those without. A positive family history
was deﬁned as having diabetes or car-
diovascular disease (including hyperten-
sion) in ﬁrst line family members such
as parents and siblings.
In total, 433 patients were included in
the analysis. This was 55% of all patients
(n = 785) treated in the department of
psychotic disorders during the inclusion
period. Age and sex distribution were sim-
ilar between included patients and total
population. Of the total population, 155
patients did not participate in the pro-
gram and another 197 patients partici-
pated partly and were excluded because
data was missing to calculate the meta-
bolic syndrome. Of the included patients,
32% (n = 138) had metabolic syndrome
according to the deﬁnition of NCEP/ATP
III, 36% (n = 158) according to the ATP
IIIa deﬁnition, and 38% (n = 165)
according to the IDF deﬁnition. In the
group of patients (n = 150) with a mea-
sure of fasting glucose, 32% (n = 48)
had metabolic syndrome according to
the deﬁnition of NCEP/ATP III, 36%
(n = 54) according to the ATP IIIa
deﬁnition, and 40% (n = 60) according
to the IDF deﬁnition. The most frequently
fulﬁlled criterion (ATP III /NCEP deﬁni-
tion) in all female patients was abdominal
obesity (66%, n = 102) and in all male
patients, hypertension (49%, n = 136).
The criterion for hyperglycemia was least
frequently fulﬁlled in male (10%, n = 27)
and female patients (10%, n = 16).
Patients with metabolic syndrome were
signiﬁcantly older, had a longer dura-
tion of disease, and signiﬁcantly more




n = 295 P
Sex (male) 65% (n = 90) 64% (n = 189) 0.816
Age, yr* 39 (30Y49) 35 (26Y45) 0.003
Duration of disease, yr* 10 (4Y17); missing: n = 13 7 (2Y15); missing: n = 30 0.008
Cardiovascular and metabolic risk factors
Positive family history of cardiovascular diseases 17% (n = 24) 11% (n = 33) 0.075
Positive family history of diabetes 14% (n = 19) 6% (n = 19) 0.012
Smoking 68% (n = 94) 58% (n = 171) 0.043
Criteria of the metabolic syndrome
Waist circumference in cm*
Female, 988 cm† 110 (1017Y122) 90 (79Y99) 0.000
Male, 9102 cm† 108 (103Y116) 91 (84Y99) 0.000
Systolic blood pressure in mm Hg,* Q130 mm Hg† 130 (120Y140) 120 (110Y130) 0.000
Diastolic blood pressure in mm Hg,* Q85 mm Hg† 80 (80Y90) 80 (70Y80) 0.000
Triglycerides in mmol/L,* Q1.7mmol/L†,‡ 2.2 (1.8Y3.1) 1.2 (0.9Y1.6) 0.000
HDL cholesterol in mmol/L*
Female, e1.3 mmol/L† 1.1 (1.0Y1.3) 1.6 (1.3Y1.8) 0.000
Male, e1.0 mmol/L† 1.0 (0.8Y1.0) 1.2 (1.1Y1.5) 0.000
Fasting glucose in mmol/L,* Q6.1 mmol/L† 5.4 (4.9Y6.3); missing: n = 90 5.0 (4.7Y5.3) missing: n = 193 0.000
HbA1c in %,* Q6.2%† 5.7 (5.5Y6.0) 5.4 (5.2Y5.6) missing: n = 4 0.000
Diagnosis
Schizophrenia 73% (n = 101) 62% (n = 183) 0.005 (df = 3)
Schizoaffective disorder 18% (n = 25) 15% (n = 44)
Other psychotic disorder 7% (n = 9) 19% (n = 55)
Other psychiatric diseases with psychotic symptoms 2% (n = 3) 4% (n = 13)
Antipsychotic drug therapy
No antipsychotic drugs 3% (n = 4) 12% (n = 34) 0.000 (df = 5)
Olanzapine (monotherapy) 17% (n = 23) 29% (n = 87)
Clozapine (monotherapy) 25% (n = 34) 16% (n = 48)
Risperidone (monotherapy) 18% (n = 25) 19% (n = 55)
Other monotherapy 18% (n = 25) 12% (n = 34)
Combinations of antipsychotic drugs 20% (n = 27) 13% (n = 37)
*Variables are presented as median (interquartile range).
†Cutoff levels for the criteria of the metabolic syndrome (ATP III/NCEP).
‡For nonfasting triglycerides, we used a cutoff of 2.2 mmol/L.
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frequently, a positive family history of
diabetes (Table 1). The diagnoses of
schizophrenia and schizoaffective disor-
der were more prevalent in patients with
metabolic syndrome than in patients with-
out metabolic syndrome. Most patients
with other psychotic disorders did not
have metabolic syndrome. Seventy-six
percent (n = 331) of all patients received 1
antipsychotic drug; patientswithmetabolic
syndrome received more often clozapine
than olanzapine, whereas patients without
metabolic syndrome received more often
olanzapine than clozapine. Furthermore,
patients with metabolic syndrome received
more often a combination of antipsychotic
drugs and less often no antipsychotic drug
than those without metabolic syndrome.
DISCUSSION
In our study, 32% of patients with
psychotic disorders fulﬁlled the criteria
for metabolic syndrome. This prevalence
was lower than reported from studies con-
ducted in patients with psychotic disorders
in North America (United States: 41%,2
Canada: 45%),7 and at the high end com-
pared to studies conducted in Europe
(Spain: 25%,3 Belgium: 28%,1 and Swe-
den: 35%).8 It was considerably higher
than in the general Dutch population: in
slightly older cohorts, it ranged from 10%
to 12% for females and from 16% to 19%
for males.9
The most concerning ﬁnding was the
high prevalence of abdominal obesity in
female patients. Even females without
metabolic syndrome fulﬁlled on average
the waist circumference criterion. Similar
ﬁndings have been described previously
and resulted in a higher prevalence of
metabolic syndrome in females compared
with males.2,3 We found an equal preva-
lence of the metabolic syndrome in males
and females; however, compared with the
general population, the prevalence of
metabolic syndrome in female psychotic
patients was more elevated than in male
patients. Similar to van Winkel et al,10 we
found the highest prevalence of metabolic
syndrome in patients with schizoaffective
disorders followed by those with schizo-
phrenia. Patients with other psychotic dis-
orders had the lowest prevalence of
metabolic syndrome, but those also had
the shortest mean duration of disease (data
not shown).
Clozapine and olanzapine have a sim-
ilar high risk of causing diabetes, dyslipi-
demia, and overweight.11 In our study,
patients with metabolic syndrome re-
ceived more often clozapine than olanza-
pine, whereas those without metabolic
syndrome received more often olanzapine
than clozapine. These differences might
be due to the different switching strategies
for these drugs. Patients with metabolic
adverse effects may have been more easily
switched to other drugs from olanzapine
than from clozapine because clozapinewas
mostly prescribed for therapy-resistant
patients, whereas olanzapine was a ﬁrst-
choice drug. This is supported by the
younger age and shorter duration of dis-
ease of the patients receiving olanzapine
compared with those receiving clozapine
(data not shown). The prevalence of meta-
bolic syndrome was also elevated in
patients receiving more than 1 antipsy-
chotic drug. Most probably, this is caused
by other factors related to the use of
combinations than the combination itself.
Correll et al12 demonstrated that antipsy-
chotic polypharmacy was related with a
higher prevalence of metabolic syndrome,
however, not after correcting for age, diag-
nosis, treatment, and body mass index.
This study was limited by the use of
HbA1c as a surrogate parameter for fast-
ing glucose. However, when only includ-
ing patients with fasting glucose measures
in the analysis, we found equal or similar
prevalences of the metabolic syndrome. In
conclusion, our study described that the
prevalence of metabolic syndrome among
patients with psychotic disorders in the
Netherlands is high and screening and
treatment are strongly required.
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Valproic AcidYInduced
Myopathy in a Patient With
Schizoaffective Disorder
To the Editors:
Anticonvulsant valproic acid (VPA) hasfound increasing use as a psychotropic
agent in the treatment of manic episodes
associated with bipolar disorder. Its com-
mon adverse effects, for example, nausea,
vomiting, weight gain, somnolence, hyper-
ammonemia, and tremor, are well known.
However, with an expanding number of
indications and VPA-exposed patients, rare
and potentially life-threatening adverse ef-
fects emerge.
Particularly, in geriatric psychiatry
dealing with patients with multimorbidity,
polypharmacy and drug interactions are a
common problem. Therefore, the service of
a routine clinical-pharmacological medica-
tion review is an important tool to recog-
nize and prevent adverse drug events.
To our knowledge, we here report the
ﬁrst case of myopathy associated with val-
proic acid in an elderly patient affected by
schizo-affective disorder.
CASE REPORT
A 85-year-old female patient with
a history of schizo-affective disorder and
dementia was admitted to a hospital be-
cause of a manic episode. She was further
affected by hypothyroidism and hyper-
tension. Her medications on admission
were quetiapine (200 mg/d), nifedipine
(10 mg/d), torsemide (10 mg/d), levothy-
roxine (75 Kg/d), and acetylsalicylic acid
(100 mg/d) for secondary prevention after
stroke. Valproic acid was initiated 4 days
after hospitalization and titrated to a
dosage of 300 mg twice daily.
On the fourth day after starting with
VPA, she complained about muscle pain
and weakness. Laboratory evaluation re-
vealed a 5-fold increase in myoglobin level
(292 Kg/L; Fig. 1), a 6-fold increase in
creatine kinase (CK) level (14.4 Kmol/L),
and slightly increased liver enzyme con-
centrations (alanine aminotransferase level,
0.72 Kmol/L and aspartate aminotrans-
ferase level, 0.93 Kmol/L). In addition,
the creatinine level was increased to
112 Kmol/L. Further blood parameters
and temperature were within the reference
range. Serum concentration of VPA was
therapeutic with 46 Kg/mL (range, 30Y
100 Kg/mL). The relatively low quetia-
pine dose resulted in a blood concentra-
tion (25 ng/mL) below the therapeutic
range (70Y170 ng/mL).
During the routine clinical pharma-
cological ward round, the case was dis-
cussed, and discontinuation of VPA and
quetiapine was decided. Long-acting
torsemide was replaced by furosemide
(10 mg/d). Pipamperone was started.
The maximum myoglobin and
CK levels (myoglobin, 345 Kg/L; CK,
17,8 Kmol/L) were detected 6 days after
stopping VPA and quetiapine. Obviously,
the half-life of VPA was increased; we
calculated it and determined a prolonged
half-life of VPA up to 30 hours (normal,
9Y16 hours; Kinetica version 4.4 [Thermo
Electron Corporation, Waltham, Mass]).
A reason for this prolongation could
be a drug interaction with the newly ad-
ministered neuroleptic pipamperone, re-
sulting in a reduced VPA clearance.
Fifteen days after cessation of VPA
and quetiapine, myoglobin and CK levels
returned to normal. Even reintroduction
of quetiapine to a maintenance dosage of
450 mg/d and the continuous administra-
tion of 40 mg of pipamperone 3 times
per day caused no deterioration of muscle
symptoms and laboratory parameters.
Psychiatric medication and the
course of myoglobin and VPA concentra-
tions are shown in Figure 1.
Myolysis commonly occurs in re-
sponse to seizures, trauma, hyperthermia,
or infections.1 We supposed VPA to be the
culprit agent based on the following: there
is a temporal relationship between the
onset of symptoms, which occurred shortly
after introduction of the drug, and the clin-
ical resolution, which followed upon dis-
continuation of the drug. Moreover, the
half-life of VPA obviously was prolonged.
In addition, there was no alternative ex-
planation for the myopathy, as the patient
had no history of seizure and no signs of
trauma, hyperthermia, or infection and, ex-
cept quetiapine, no drugs, which are known
to cause myopathy such as statins.
Although rare, a few other case de-
scriptions to support our hypothesis were
found. The occurrence of acute rhabdo-
myolysis triggered by valproic acid was
reported in a patient with carnitine pal-
mitoyltransferase type II deﬁciency.2
Furthermore, cases of VPA-induced
FIGURE 1. Psychiatric medication and course of myoglobin concentration.
Letters to the Editors Journal of Clinical Psychopharmacology & Volume 29, Number 4, August 2009
402 www.psychopharmacology.com * 2009 Lippincott Williams & Wilkins
9Copyright @ 200  Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
myopathy in children were described in
the literature.3Y5
The mechanism of this adverse
effect is unknown. A reasonable explana-
tion could be the inhibition of the mito-
chondrial A-oxidation by valproic acid
and its metabolite 2-n-propyl-4-pentenoic
acid. This has been shown in rat liver
and could also lead to impairment of
A-oxidation in muscle tissue.6
With regard to quetiapine, several
case reports describing rhabdomyolysis or
a massive increase in serum CK associated
with quetiapine therapy or overdose were
taken into consideration.7Y10 In the pre-
sent case, the quetiapine plasma level was
subtherapeutic at the onset of symptoms.
Moreover, after readministration, myoglo-
bin and CK levels remained normal.
Admittedly, Meltzer et al11 described
a few cases with other atypical antipsy-
chotics in which increased serum CK
activity decreased to normal despite con-
tinued treatment. Therefore, quetiapine
and a pharmacodynamic drug interaction
between quetiapine and VPA cannot com-
pletely be excluded as cause for the de-
scribed adverse drug reaction.
Overall, using known probability
assessment scores, a possible adverse drug
reaction had occurred.12,13
In conclusion, psychiatrists should
be aware of VPA causing myopathy apart
from atypical antipsychotic drugs in older
people. Furthermore, cooperation with clin-
ical pharmacologists is a helpful tool to rec-
ognize and manage adverse drug events.
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Allopregnanolone Levels





Severe premenstrual syndrome (PMS) ischaracterized by disabling physical and
psychological symptoms that occur during
the luteal phase of the menstrual cycle.
Allopregnanolone has been implicated in
the pathophysiology of mood disorders,
stress, and possibly PMS and premen-
strual dysphoric disorder.1 There is some
evidence that response to treatment of
PMS correlates with decreased allo
levels.2 We previously found in a small
pilot study that women with PMS who
improved with selective serotonin reup-
take inhibitor (SSRI) treatment had sig-
niﬁcantly lower allo levels at treatment
end point than the unimproved subjects.3
However, a major limitation of that study
was that pretreatment allo levels were not
evaluated, and associations between SSRI
treatment and changes in allo could not be
determined. The aims of the present study
were to identify changes in allo levels after
SSRI treatment and determine whether the
changes in allo levels were related to im-
provement in PMS symptoms. Based on
our previous pilot study, we hypothesized
that high allo levels decreased with SSRI
treatment and that the changes were as-
sociated with symptom improvement. We
also hypothesized that low allo levels at
baseline increased, as previously shown
in patients with depression, and that the
changes were associated with improve-
ment of dysphoric symptoms.4
This was a prospective study of 46
women with PMS, whose conditions were
diagnosed with clearly deﬁned criteria in-
cluding daily symptom ratings and treated
with sertraline as described elsewhere.5
All participants who had serum samples
collected within 8 days before menses
both before and after sertraline treatment
and met the criteria for this study were
included. Inclusion criteria included reg-
ular menstrual cycles in reference range,
a positive result for urine test indicat-
ing probable ovulation, and general good
health. Exclusions included any hormone
use, other treatments for PMS, any major
Axis I psychiatric diagnosis currently or
in the past year, lifetime diagnosis of bi-
polar disorder or psychosis, and alcohol or
drug abuse. Flexible regimens were used;
all but 4 subjects had luteal phase dosing
(14 days before estimated menses through
2 days after the onset of menses) with
sertraline dosages of 50 or 100 mg/d. All
subjects signed consent forms approved
by the university institutional review
board.
Serum samples were collected at ap-
proximately day 4 T 3 days before menses
in an untreated screen cycle and after 2 to
3 months of SSRI treatment. The cycle day
was conﬁrmed by the date of menses after
each blood draw using backward count
from the ﬁrst day of menses. The samples
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were stored at j80-C and measured in
the laboratory of Dr Cheryl Frye according
to previously established methods.6 The
minimum detectable limit of the assay was
100 pg. The intra-assay and interassay
coefﬁcients of variance were 0.12 and 0.15,
respectively.
Premenstrual syndrome symptoms
were rated daily by the participants, and
scores were obtained in the same men-
strual cycles as the allo measures. The
validated daily symptom report (DSR)
included 17 mood, behavioral, and phys-
ical symptoms of PMS that were rated
on a 5-point scale ranging from 0 (not
present) to 4 (very severe).7 Premenstrual
symptom scores were obtained by sum-
ming the daily ratings for the last 6 days
of each menstrual cycle.
General linear regression models
were used to examine the associations
between baseline and end point measures.
Baseline allo was examined as a contin-
uous variable and also as a class variable
divided into tertiles and in 2 groups to
examine the a priori hypothesized changes
for high and low baseline allo levels. Re-
sults were consistent. Multivariable linear
regression models were adjusted for cycle
day and for a history of depression as a
potential confounder. Changes in premen-
strual symptoms were compared between
the 3 baseline allo groups. F, Student t,
and W2 or Fisher exact tests were used
as appropriate for the data, with 2-tailed
P G 0.05 considered statistically signiﬁ-
cant. The SAS version 9.1 (SAS Institute,
Cary, NC) was used for all analyses. Post
hoc power calculations were performed
and indicated 81% power for aim 1 but
only 43% power to detect a signiﬁcant
improvement in symptoms compared be-
tween baseline allo groups.
The mean (SD) age of the 46 partici-
pants was 31.1 (7.0) years. The mean cycle
day before menses wasj3.70 (2.74) at the
pretreatment baseline andj3.52 (SD 2.21)
at treatment end point. The mean allo level
was 2.55 (1.22) ng/mL at baseline and 2.46
(SD 1.06) ng/mL at treatment end point.
Thirty-nine percent of the subjects (18/46)
had a history of depression.
The change in allo after sertraline
treatment was signiﬁcantly associated
with baseline allo levels in a linear
regression model adjusted for cycle day
(P G 0.0001). We examined the same
models with baseline allo levels divided
into tertiles as hypothesized. Allo levels
signiﬁcantly decreased in the high base-
line allo group (P G 0.001) and signiﬁ-
cantly increased in the low baseline allo
group (P = 0.026) compared with the
baseline mid allo group. Allo levels did
not change signiﬁcantly in the mid group
(P = 0.652). We repeated these analyses
with baseline allo levels divided at the
median (2.24 ng/mL) with consistent
results: allo levels signiﬁcantly increased
in the low baseline allo group compared
with the high baseline allo group (P G
0.0001). There was no difference in allo
levels compared between women with and
without a history of depression, either at
baseline (P = 0.72) or after sertraline
treatment (P = 0.30).
Sixty-three percent of the subjects
(29/46) improved with SSRI treatment as
deﬁned by 50% improvement or more in
the total premenstrual DSR score at end
point compared with baseline. We exam-
ined the association of baseline allo levels
with the change in 7 selected DSR symp-
toms that were hypothesized a priori to be
associated with allo levels. Improvements
in feeling out of control (P = 0.004),
depression (P = 0.022), and hopelessness
(P = 0.051) were associated with baseline
allo. For each of these symptoms, the base-
line low and mid allo groups improved,
whereas those with high baseline levels
had little change in symptoms (Table 1).
There was no signiﬁcant association be-
tween baseline allo groups and improve-
ment of the total DSR score (P = 0.391).
DISCUSSION
In this investigation, the subjects with
low baseline allo levels had a signiﬁcant
rise in allo after SSRI treatment, whereas
those with high baseline allo levels had
signiﬁcant decreases in allo. Although
these changes may simply reﬂect regres-
sion to the mean, other interpretations can
be considered. In studies of patients with
depression, low allo levels were associ-
ated with depressive symptoms; the allo
levels increased and depressive symptoms
decreased with ﬂuoxetine treatment,4 sug-
gesting that a dysregulation of proges-
terone metabolism may be corrected with
an SSRI.8 Other studies found that both
high and low levels of allo had negative
associations with mood in postmeno-
pausal women treated with progesterone,
suggesting a bimodal association between
allo and mood.9 Monteleone et al10 re-
ported that patients with PMS had sig-
niﬁcantly lower luteal phase levels of
allo compared with normal controls and
a reduced response to a gonadotropin-
releasing hormone test, suggesting that
impairment of a F-aminobutyric acidY
mediated anxiolytic effect led to the re-
duced sense of well-being in the luteal
phase. In contrast, other studies indicated
that high allo concentrations were as-
sociated with premenstrual dysphoric
(PMDD) and panic disorders.11,12 It is
also possible that the ﬂuctuations of allo,
that is, the long-term exposure and with-
drawal of the neurosteroid over the men-
strual cycle, result in anxiogenic effects.13
Baseline allo levels were signiﬁcantly
associated with differential improvement
in speciﬁc and primarily dysphoric symp-
toms. However, neither levels nor changes
of allo were associated with total premen-
strual symptom scores. Although noting
that the power to detect associations be-
tween changes in allo and symptom reduc-
tion was low in this pilot study (43%),
existing data suggest that allo may not be
associated with all symptoms that are in-
cluded in the highly heterogeneous deﬁ-
nition of the syndrome.
Further studies to assess ﬂuctuations
of allo over time before and after sertraline
therapy may be informative. The study did
not include a placebo-treated group, and
comparisons of allo changes between
drug- and placebo-treated groups are
needed to support or refute these ﬁndings.
These pilot data did not allow further
investigation of the dosing duration and
diagnostic differences (PMS vs PMDD),
which may be valuable to study in the
future. Single luteal measures are difﬁcult
to interpret with conﬁdence given the
variability in luteal phase allo levels, and
daily luteal measures might improve
precision in further studies. Inclusion of
follicular and ovulatory hormone levels
would also provide a more complete









Hopelessness 6.77 (3.81Y9.74) 6.62 (3.45Y9.79) 2.03 (j1.03 to 5.09) 0.051
Out of control 7.37 (4.14Y10.62) 10.25 (6.78Y13.72) 2.2 (j1.14 to 5.56) 0.004
Decreased social
activity
6.69 (3.4Y9.95) 6.12 (2.63Y9.61) 1.83 (j1.54 to 5.20) 0.091
Depression 9.23 (6.52Y11.92) 8.51 (5.62Y11.4) 3.59 (0.789 to 6.33) 0.009
*Values are the mean absolute change in the DSR symptom score with 95% conﬁdence interval.
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investigation of the associations between
allo and PMS symptoms.
Overall, the data suggest that allo
levels differ in subjects with a different
complement of symptoms and that the
effect of an SSRI depends on both the
speciﬁc symptoms and the endogenous
allo levels. Further clariﬁcation of the role
of allopregnanolone in PMS may contrib-
ute to understanding the pathophysiology
of the syndrome and to predicting which
women will respond to treatment with
current medications such as SSRIs. If allo
is ultimately found to be important in the
etiology of PMS or PMDD, novel treat-
ments targeting allo or other GABAergic
targets might be developed.
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Influence of Antidepressant
Use on Glycemic





Depression is a common comorbidityin patients with diabetes mellitus1 and
is frequently treated with antidepressants.
Depression in diabetic patients is associ-
ated with poor glycemic control,2 which in
turn is a risk factor for microvascular and
macrovascular complications. Antidepres-
sants, however, may also interfere with
glucose homeostasis and thereby further
complicate glycemic control. It has been
postulated that the interference of anti-
depressants on glucose homeostasis is
bidirectional depending on the complex
pharmacology of antidepressants. An in-
crease in norepinephrinic function and a
blockade of the histamine H1 and 5-HT2C
receptors seem to increase glucose levels
because of reducing both insulin release
and insulin sensitivity. In contrast, an in-
crease in serotonergic function seems to
increase insulin sensitivity and reduce
glucose levels.3 This implies that those
antidepressants that inhibit the serotonin
reuptake transporter may have insulin-
sparing effects and could be advantageous
for patients with diabetes mellitus treated
for comorbid depression. However, evi-
dence on this subject is still limited. In
this open-label comparative study, we eval-
uate the change in insulin requirements
of 4 patients starting with a serotonergic
antidepressant compared with 8 diabetic
patients not using any antidepressant.
The source population consisted of
patients attending the diabetes outpatient
clinic of the Orbis Medical Center. The
Orbis Medical Center is a 700-bed teach-
ing hospital serving more than 180,000
patients in the south of the Netherlands.
The diabetes outpatient clinic is visited
by patients with new-onset diabetes and
by diabetic patients who need additional
care. Patients visit the outpatient clinic on
a 3-monthly regular basis. Advice is given
regarding (1) insulin injection regimen
based on glucose self-monitoring (com-
bined with oral antidiabetics), (2) handl-
ing diabetic complications, and (3) lifestyle
such as dietary advice. Some patients reg-
ister their glucose measurements and the
amount of injected insulin regularly in a
diabetes diary. For all patients, the current
amount of injected insulin and changes in
the amount of injected insulin are also
recorded by the diabetic nurse in the
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electronic patient record. Laboratory data
are collected in the same record.
Patients were included if they met
the following inclusion criteria: (1) they
started with a serotonergic antidepressant
(index date), (2) used this antidepressant
for at least 180 days, (3) had no prescrip-
tion for any antidepressant for 180 days
before the index date (wash-out period),
(4) were 18 years or older at the index
date, and (5) used insulin for at least
30 days before the index date. Patients
were followed up for 210 days. Seroto-
nergic antidepressants were deﬁned
according to a model classifying antide-
pressants based on their binding proper-
ties to the most common transporter and
receptor sites. Serotonergic antidepres-
sants included citalopram, clomipramine,
duloxetine, escitalopram, ﬂuoxetine, ﬂu-
voxamine, paroxetine, sertraline, and ven-
lafaxine.4 To study the natural course of
insulin requirements during the study
period, we randomly selected 2 nonusers
of antidepressants for each user. The index
date for nonusers was deﬁned as the in-
clusion date, and nonusers were included
if they met the following inclusion crite-
ria: (1) they were 18 years or older at the
index date, (2) used insulin for at least
30 days before the index date, and (3) did
not use any antidepressant at inclusion or
during the follow-up period of 210 days.
The primary outcome of this study
was the mean relative difference of insulin
requirements over time (at 0, 30, 60, 120,
and 180 days after the index date). The
mean insulin requirement at 30 days be-
fore the index date was taken as the ref-
erence value. Insulin requirements at
different time points were obtained from
diabetes diaries and/or from the electronic
patient record. We also collected the most
recent available HbA1C values before the
index date and between 90 and 180 days
after the index date.
The following covariates were ob-
tained to present individual differences be-
tween subjects: age, sex, body mass index
(BMI), changes in eating behavior for a
period of 180 days before the index date,
diabetes type, duration of diabetes, use of
oral antidiabetics, current use of poten-
tially hypoglycemia- and hyperglycemia-
inducingmedications, and depression score
at the index date. Current use of antidiabetic
medication and use of hyperglycemia-
or hypoglycemia- inducing comedication
were deﬁned as use of such medication
at the index date. Hyperglycemia- and
hypoglycemia- inducing comedications
were identiﬁed by a literature search.5
The Self-Rating Depression Scale (SDS)
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The prevalence of each characteristic
was determined at index date. The non-
parametric Mann-WhitneyU test was used
to compare changes in mean insulin dose
and HbA1C at different time points be-
tween users and nonusers.
Four serotonergic antidepressant
users and 8 nonusers were included from
April 2007 to March 2008. Table 1 pro-
vides a description of the individual users
and nonusers. The mean insulin dosage
30 days before index date was 79.8 IU/d
for the users and 81.0 IU/d for the non-
users (P = 0.68). The mean insulin dose
increase in the period from 30 days before
the index date to 180 days after the index
date was 2.4% for the users and 18.3%
for the nonusers (P = 0.15). Nonuser
3 showed the biggest insulin dose increase
in this period (86.4%). Excluding nonuser
3 from the analysis, the mean insulin dose
increase in the nonusers in the period from
30 days before index date to 180 days after
the index date was 8.5%. The standardized
mean insulin doses did not reach statistical
difference between users and nonusers
at any time during follow-up.
HbA1c levels at index date were 8.1%
for the users and 7.6% for the nonusers
(P = 0.81). The mean relative decrease of
HbA1c levels during follow-up was 7.2%
for the users and 0.5% for the nonusers
(P = 0.37).
DISCUSSION
Insulin requirements in patients start-
ing with a serotonergic agent increased
2.4% during follow-up compared with
18.3% in the nonusers. The HbA1C levels
decreased in users of serotonergic agents
compared with nonusers. However,
these differences were not statistically
signiﬁcant.
A limitation to this open-label com-
parative study is that it was underpow-
ered for statistical signiﬁcance as is
illustrated by the fact that a single patient
was responsible for an important increase
inmean insulin requirements in the nonuser
group. However, evidence from earlier
studies with other outcome parameters
showed the same patterns as we have
found. In patients with type 2 diabetes
mellitus and in nondiabetic patients, the
use of ﬂuoxetine and the serotonergic
anorectic agent fenﬂuramine increased
insulin sensitivity in the short term.6,7 In
a recent longitudinal follow-up database
study of patientswith types 1 and 2 diabetes
mellitus, users of selective serotonergic
reuptake inhibitors (SSRIs) showed a 13%
decrease in insulin requirements during
SSRI use, whereas no change was found
in users of tricyclic antidepressants and
nonusers.8
We analyzed types 1 and 2 diabetic
patients together and did not stratify ac-
cording to diabetes type. If SSRIs improve
insulin sensitivity, you should not expect
improvement in type 1 diabetic patients
because insulin sensitivity is not impaired
in this group of patients. However, previ-
ous evidence in healthy subjects and sub-
jects with type 1 diabetes mellitus revealed
that the use of antidepressants increased
insulin sensitivity and may even cause
hypoglycemia.9,10 Because it has been
documented that SSRI antidepressants
may improve insulin sensitivity in both
types of diabetes, we feel that it is justiﬁed
to include both types of diabetic patients in
our study and to pool the results.
An interesting question is whether
the insulin-sparing effects we have found
are caused by a pharmacological effect of
serotonergic agents or by a change in the
course of depression. There are several
arguments against the assumption that the
course of the depression has inﬂuenced
our study outcomes. First, patients recov-
ering from a depression are more likely to
have an increased food intake resulting in
increased insulin requirements. We have
found the opposite effect. Second, refer-
ring to the SDS scores the patients in our
study population were not clinically dep-
ressed. Third, just before the index date,
users and nonusers showed similar insu-
lin requirements (although there was not
enough power to detect any dissimilarity).
Fourth, questions about changes in eating
behavior 180 days before the index date
did not reveal any differences between the
users and nonusers.
In conclusion, the question whether
antidepressants have insulin-sparing ef-
fects remains unsolved at this stage.
However, the results of this open-label
comparative study show the same patterns
as other studies: serotonergic agents may
increase insulin sensitivity, lower glucose
levels, decrease HbA1C, and decrease in-
sulin requirements.Therefore, treating a de-
pressed diabetic patient with a serotonergic
agent combined with an accurate glucose
self-monitoring seems a good option.
Additional research with more patients is
needed to conﬁrm these results and to
establish the clinical relevance of these
ﬁndings.
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Modaﬁnil is a wake-promoting agentthat is pharmacologically different
from other stimulants.1,2 It has been in-
vestigated in healthy volunteers, as well
as in individuals with clinical disorders
associated with excessive sleepiness, fa-
tigue, impaired cognition, and other symp-
toms.1,2 In sleep-deprived individuals,
modaﬁnil improves mood, fatigue, sleep-
iness, and cognition to a similar extent
as caffeine, but has a longer duration of
action.1,2 Evidence for improved cogni-
tion in nonYsleep-deprived healthy volun-
teers is controversial.1,2 Modaﬁnil has
been approved by the US Food and Drug
Administration for the treatment of 3
disorders. It improves excessive sleepiness
and decreases illness severity in narco-
lepsy, shift work sleep disorder, and sleep
apnea with excessive sleepiness despite
optimal continuous positive airway pres-
sure therapy. However, its impact with
respect to workplace safety and on the
morbidities associated with these disor-
ders has not been determined. Here, we
report a case of psychotic symptoms in-
duced by modaﬁnil treatment.
Our patient was a 25-year-old woman
with a 10-year history of narcolepsy. Her
main symptoms were excessive daytime
sleepiness and severe sleep paralysis. Nei-
ther catalepsy nor hypnagogic hallucina-
tions were observed. She had been treated
with methylphenidate for 5 years in a pre-
vious sleep clinic. However, because of
insufﬁcient improvement of her symp-
toms, she moved back to her hometown
for treatment of her narcolepsy. To alle-
viate her symptoms, modaﬁnil was ad-
ministrated and titrated up to 300 mg/d
in our hospital. The patient’s symptoms
improved markedly and her Epworth
Sleepiness Scale score dropped from 17
to 6 points. However, she did experience
dry mouth and tachycardia while on ther-
apy from day 1 to day 5. After 5 days, she
continued on 300-mg modaﬁnil per day
without any side effects. Approximately
6 months after the initiation of modaﬁnil
therapy, she reported seeing white smoke
coming from her computer. She also
reported an experience where she felt
like a few people were behind her and
she heard them talking when there was
no one else present. These symptoms ap-
peared 12Y24 hours after modaﬁnil ad-
ministration. Because of her visual and
auditory hallucinations, and delusions of
reference, modaﬁnil therapy was dis-
continued and these psychotic symptoms
disappeared. However, because her nar-
coleptic symptoms reappeared, modaﬁnil
dosing was restarted every other day.
Although hallucinations occasionally re-
curred, she learned to cope with them
through psycho-education.
There have been ﬁve case reports of
psychosis associated with modaﬁnil ad-
ministration.3Y7 Among these, modaﬁnil
was used for the treatment of narcolepsy
in two cases.4,7 One described a 17-year-
old man who developed persecutory and
referential delusions in addition to audi-
tory and visual hallucinations while taking
400 mg modaﬁnil per day.4 Prior to the
onset of symptoms, he had tolerated the
same dose for a year without ill effect.
This case was quite similar to ours. The
other narcolepsy related case involved a
31-year-old woman who developed tem-
porary persecutory delusions and auditory
hallucinations after taking an overdose
of 500 mg modaﬁnil and 300 mg of
caffeine.7 The other 3 cases included a
schizophrenic patient, 3 a research vol-
unteer, 5 and a patient with a mood dis-
order and substance abuse.6
Although the precise mechanism of
modaﬁnil is not known, the waking effects
of modaﬁnil are thought to be mediated
by activation of noradrenergic > 1 recep-
tors based on several animal studies.1,2
In addition, haloperidol did not block the
behavioral effect of modaﬁnil in animals,
although it had blocked the behavioral
effects of amphetamine. This suggests
that modaﬁnil has a different mechanism
of action compared to other stimulants.8
Recent animal studies have demonstrated
that modaﬁnil enhances the extracellular
levels of dopamine promoting wakeful-
ness. It has also been associated with do-
pamine release from striatal neurons.9,10
These dopaminergic effects may be re-
lated to the psychotic symptoms induced
by modaﬁnil treatment.
Our case report suggests that long-
term administration of modaﬁnil may in-
duce psychotic symptoms, as have other
stimulants such as amphetamines. Al-
though rare, the potential for psychotic
symptoms when using modaﬁnil therapy
should be kept in mind.
Norio Yasui-Furukori, MD, PhD
Masato Kusunoki, MD
Sunao Kaneko, MD, PhD
Department of Neuropsychiatry
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Response to Shen J, Kobak K,
Zhao Y, et al. Use of
Remote Centralized Raters






W e applaud Shen et al
1 for their ef-
forts to explore new methods that
might enhance the ability of studies to
successfully detect drug signals. The work
is important because, for reasons that are
not fully elucidated, a steadily increasing
placebo response and decreasing drug
response in schizophrenia trials have
been noted over time, serving to poten-
tially jeopardize signal detection of new
agents.2 In our view, the critical, unan-
swered question raised by the work1 is
whether the use of centralized raters
represents an improvement over current
practice with respect to solving the
problems noted. The article1 might have
been more informative in this respect if
it had described a comparison to site-
based ratings in the same study as a con-
trol group. It would also be helpful to
have more information on the severity
and character of the psychotic symptoms
in the report1 because these symptoms
could affect patients’ cooperativeness with
the central ratings procedures.
Current practice is to use trained
investigators as site raters. We know
that these raters have the capacity to
make valid and reliable assessments of
the mental state of patients. To date, site
as opposed to centralized raters’ ability
to separate drug from placebo has sup-
ported the approval of every antipsychotic
agent and, in fact, every commercially
available central nervous system drug.
In a recent review, Kemp et al2 reported
the diminution of drug-placebo differ-
ences when compared with earlier trials.
Many potential explanations have been
put forth, from overall changes in subject
characteristics and motivation, to increas-
ingly high clinician expectations about
antipsychotic efﬁcacy, to actual changes
in studied drug efﬁcacy. Unfortunately, al-
though we know there is a problem, there
is no clear answer as to how it can best be
solved.
Advocating for a centralized ratings
approach in the absence of data that it is
superior to site-based ratings seems to be
premature and potentially ill-advised. It
may be the case that studies fare worse
with central raters than they do with site
raters who are able to perform in-person
interviews. We have no information either
way. Yet studies can easily be designed
that compare same-patient ratings by site
raters with those of centralized raters.
Such studies, if done carefully, could af-
ford the ﬁeld a useful starting point to
evaluate the potential beneﬁts of central-
ized ratings with respect to placebo re-
sponse, drug response, and, ultimately,
signal detection.
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1. Shen J, Kobak K, Zhao Y, et al. Use of remote
centralized raters via live 2-way video in a
multicenter clinical trial for schizophrenia.
J Clin Psychopharmacol. 2008;28:691Y693.
2. KempAS, SchoolerNR,Kalali AH, et al.What
is causing the reduced drug-placebo different
in recent schizophrenia clinical trials and what
can be done about it? SchizophreniaBull. 2008;
advance access published online August 22,
2008. Available at: http://www.
movementdisorders.org/congress/congress09/
abstract_info.php.
Reply to Comments by
Grunze et al
To the Editors:
We agree with Dr Grunze et al on theneed for empirical data on the re-
lative efﬁcacy of site versus central raters
in both patient inclusion and outcomes
assessment. It is because of this that Med-
Avante has collaborated with several spon-
sors in conducting multiple head-to-head
comparisons of site and central raters. The
report by Shen et al1 is one of the ﬁrst pub-
lications from these efforts and describes
only the central raters’ outcomes as a way
of addressing the feasibility (as noted by
Grunze et al, not the superiority) of the
methodology. It does clearly demonstrate
both the technical feasibility of the video-
conferencing methodology and the ability
to assess patients with psychosis with this
method.
We applaud these sponsors because
research addressing methodological issues
usually requires modiﬁcations of the study
design that are not directly related to as-
sessing drug efﬁcacy or safety and may
require additional costs. However, to ade-
quately answer methodological questions,
sponsors must be willing to share all data
that will shed light on these questions. This
may involve releasing data that are usually
considered proprietary because it may be
difﬁcult to disentangle the issue of evalua-
ting assessment methodology from exam-
ining efﬁcacy/safety of the compounds
being studied. As to the level of severity of
the patients in the trial, the inclusion criteria
required that the subjects be inpatients who
were hospitalized owing to the acute exac-
erbation of their schizophrenia.2
Although there are as yet no published
data on the relative efﬁcacy of site versus
central raters on signal detection, there are
empirical data on the individual compo-
nents of central ratings and increased signal
detection. These have been reviewed else-
where3 and include larger signal detection
with ratings of better quality, higher reli-
ability, and improved blinding.
Finally, although the authors cor-
rectly state that site raters have been used
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to support the approval of virtually every
central nervous system drug to date, this
does not necessarily mean it is the best
process to achieve the ends of accurate
assessment of drug efﬁcacy or safety. Forty
years ago, virtually all manuscripts were
created on typewriters, but the advent of
computerized word processing provided a
far better methodology in virtually all
respects. There is enormous concern about
the increasing number of failed trials and
the lack of precision in patient selection and
outcomes assessment that might contribute
to that phenomenon. We welcome the
opportunity to further research the merits
of this approach and to let all of the
empirical data guide us in evaluating its
relative merit.
Kenneth A. Kobak, PhD
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The recent increase in governmentsponsored pragmatic clinical trials in
psychiatry has opened a new vista in un-
derstanding the effectiveness of drugs in
a real world situation or on real world
patients that are characteristic of those
seen in daily clinical practice. However,
industry-sponsored clinical trials are main-
ly intended to pass regulatory authorities
and assess efﬁcacy rather than effective-
ness in a narrowly deﬁned patient popula-
tion in somewhat laboratory-controlled
conditions.
The famous Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE)
schizophrenia study, funded by the National
Institute of Mental Health,1 was carried out
to compare effectiveness and tolerability of
atypical and typical antipsychotics in treat-
ment of schizophrenia. One thousand four
hundred sixty patients with Diagnostic and
Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV ) schizophrenia
were included, and those with ﬁrst-episode/
treatment-resistant schizophrenia were ex-
cluded. Patients with concomitant medica-
tions, medical illnesses, and/or substance
abuse disorders were however included
(in contrast to many other clinical trials
conducted for regulatory purposes).
The dosing and dose equivalence used
in the CATIE study2 were somewhat dif-
ferent from American Psychiatric Associa-
tion guidelines3 especially for risperidone
and ziprasidone. Clinical Antipsychotic
Trials of Intervention Effectiveness investi-
gators explain this difference by stating that
‘‘the average prescribed doses of these
drugs in United States in patients with
schizophrenia during the period in which
the study was conducted (14 mg olanza-
pine/day, 3.8 mg risperidone/day, 388 mg
quetiapine/day, and 125 mg ziprasidone/
day) were generally similar to the ones we
used.’’4 However, the mean modal doses in
CATIE were, in fact, approximately 40%
higher for olanzapine and quetiapine and
3% for risperidone, whereas 11% lower
for ziprasidone,5 making this an impor-
tant issue to be addressed before trial
completion.
Interestingly, this meant making cer-
tain assumptions about the dosageVwhere
dosage of olanzapine used (30 mg) was
much higher than what most practitioners
prescribe; that of risperidone (6 mg) was
well below the upper range of clinical use.6
Yet, fewer than half of patients participating
in the ﬁrst phase received the maximum
dose allowed of their assigned medication;
however, rates of discontinuation owing to
intolerability ranged from 10% to 19%.
This raises an important query as towhether
the 15% to 28% of patients who discon-
tinued because of lack of efﬁcacy received
the maximum allowable dose.5
Another interesting thing to ponder
over is why was the dosage of antipsy-
chotics restricted to that used in the
CATIE trial? We feel that the choice of
drug and its dosage (either typical or
atypical antipsychotics) in the study de-
sign was carefully selected to avoid de-
velopment of extrayramidal adverse
effects (EPAs) and tardive dyskinesia
(TD), as these could have led to a sharp
increase in dropout rates. Although the
drugs used were Food and Drug Admin-
istration approved, the dosages of risper-
idone, ziprasidone, and perphenazine were
kept at lower levels despite American Psy-
chiatric Association recommendations.3
Risperidone is also more likely to cause
EPA and act like a typical antipsychotic7
in dosages of more than 6 mg/d. Perphe-
nazine was selected and used in modest
dose for obvious reasons, as it causes less
EPA and actsmore like a second-generation
than a ﬁrst-generation antipsychotic such
as haloperidol or chlorpromazine.6
The CATIE study observed that olan-
zapine (64%) was most effective for dis-
continuation rates, and efﬁcacy of the
conventional antipsychotic agent perphe-
nazine seemed similar to that of quetiapine,
risperidone, and ziprasidone (74%Y82%).
Neither were there higher rates of EPA
noted on the Simpson-Angus Scale.6 The
rates of discontinuation because of intoler-
ability (n = 213 [15%]) were also sta-
tistically similar among the treatment
groups. All this makes us wonder about
the differences observed, if there was any.
Coming to the adverse effects, the
CATIE study noted a high prevalence of
metabolic syndrome (MS) in study partic-
ipants (42%), with 51.6% of women and
36% of men developing MS during course
of the study. These numbers are not
surprising considering that most partici-
pants were already on prior treatment.
Yet, these rates are much higher than the
National Health and Nutrition Examination
Survey (NHANES) trials8 in both men
(CATIE vs NHANES: 36% vs 19.7%) and
women (51.6% vs 25%). The reported MS
rates of CATIE is also higher than
NHANES study, CLAMORS study
(24.6%),9 Finland study (19%),10 and
what we have reported earlier (10%).11
Whether these differences in results are
because of genetic or dosage variations
between the studies are yet to be explained.
Olanzapine, quetiapine, and perphe-
nazine treatments were associated with
elevations of cholesterol, triglycerides,
and fasting glucose levels but not risper-
idone and ziprasidone. The results with
risperidone are surprising because it has
been indicated that hyperlipidemia may be
a consequence of risperidone treatment
also.11 Risperidone, declared a safe drug
by CATIE, has also been shown to
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produce abnormal glucose levels12,13 and
increases the risk for diabetes.13,14 Simi-
larly, although obesity has been noted to
be maximum with olanzapine and mini-
mal with risperidone in CATIE trials,
other studies with more realistic dosages
of risperidone have indicated no differ-
ences between the 2, either in clinically
signiﬁcant weight gain12,14 or in overall
weight and body mass index changes.15
From the previously mentioned argu-
ments, one may conclude that lower dos-
age of risperidone in the CATIE trial may
be responsible for its better adverse-
effect proﬁle, which may also be true for
ziprasidone.
DISCUSSION
Unfortunately, even after careful se-
lection of drugs and dosages by CATIE in-
vestigators to avoid EPA and prevent TD,
the higher rate of atypical antipsychotic-
induced MS is alarming. We need to
answer several questions that arise here
such as: (1) Is it old gold, and do we start
preferring typical over atypical antipsy-
chotics to prevent MS? (2) If typicals are
preferred, what about TD of typical anti-
psychotics? (3) Can we consider the life-
threatening complications of MS to be
worse than TD?
These questions need to be addressed
urgently in future research on antipsychotic-
induced MS. Currently, the long-term
effects of MS are comparatively well
known in the form of cardiovascular and
cerebrovascular disorders, but the long-
term effects of antipsychotic-induced MS,
which is a recent phenomenon, are not
known clearly. Although TD was seen as a
disabling effect of older antipsychotics, it
was not really life threatening, and other than
being cosmetically unacceptable, it was not
actually causing anyhealth-related problems.
This is unlikeMS, which may be considered
as a form of neo-TD.13 Even the course and
prognosis of antipsychotic-induced MS are
somewhat controversial, especially regarding
its reversibility and its dose dependence.16
We need more research data on the course
and outcome of MS before making a ﬁnal
call. It may be preferable to extend the
follow-up of CATIE patients. In the interim,
patients could be treated with second-
generation antipsychotics for ﬁrst 6 weeks
and then switched and maintained on ﬁrst-
generation antipsychotics as soon as risk
factors start to develop.16
Narayana Manjunatha, MBSS,
DPM, MD
National Institute of Mental Health
and Neurosciences
Bangalore, India
Sahoo Saddichha, BA, MBBS, DPM
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Comments on ‘‘An
Innovative Design to
Establish Proof of Concept
of the Antidepressant Effects
of the NR2B Subunit
Selective N-Methyl-D-
Aspartate Antagonist, CP-




I read with great interest the recent articleby Preskorn et al1 about the efﬁcacy of
an NR2B subunit-selective N-methyl-D-
aspartate (NMDA) receptor antagonist
CP-101,606 in treatment-refractory
patients with major depressive disorder
(MDD). This study was a randomized,
double-blind, placebo-controlled study,
and this study had 2 treatment periods.
In period 1, subjects ﬁrst received a 6-week
open-label trial of paroxetine (20 mg)
and a single-blind, intravenous placebo
infusion. Period 1 nonresponders (n =
30, deﬁned as e20% improvement in the
17-item Hamilton Depression Rating
Scale score at the end of period 1 com-
pared with the screening visit) then
received a randomized double-blind single
infusion of CP-101,606 or placebo plus
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continued treatment with paroxetine
(40 mg) for up to an additional 4 weeks
(period 2). On the prespeciﬁed main out-
come measure (Montgomery-A˚sberg De-
pression Rating Scale total score at day
5 of period 2), CP-101,606 treatment sig-
niﬁcantly produced a greater decrease than
the placebo group. In addition, Hamilton
Depression Rating Scale response was
60% for the CP-101,606Ytreated group
versus 20% for placebo group. Interest-
ingly, 78%of CP-101,606Ytreated respond-
ers maintained response status for at least
1 week after the infusion.1 There were no
deaths or discontinuations due to adverse
events or abnormal laboratory ﬁndings. Ad-
verse events from the CP-101,606Ytreated
group (n = 15) and the placebo-treated
group (n = 15) were 55 and 61 adverse
events, respectively. Six patients of the CP-
101,606Ytreated group experienced a dis-
sociative reaction (2 mild, 2 moderate, and
2 severe), and 2 subjects of the placebo-
treated group also experienced a mild dis-
sociative reaction. Most adverse events
including feeling abnormal, dizziness, par-
esthesia, somnolence, dry mouth, and ab-
normal urine odor were mild and did not
differ between the CP-101,606Ytreated
group and the placebo-treated groups.
These ﬁndings suggest that the NR2B sub-
unit of NMDA receptor would be a fruitful
target for the development of a new anti-
depressant with more robust effects and a
faster onset compared with those currently
available antidepressants.1
A growing body of evidence suggests
that glutamate plays a key role in the path-
ophysiology of MDD.2Y5 First, a single
dose of the NMDA receptor antagonist
ketamine produced a rapid and short-lived
antidepressant effect in treatment-refractory
patients with MDD.4 A subsequent double-
blind placebo-controlled crossover study
found that a single intravenous dose of
ketamine (0.5 mg/kg over 40 min) resulted
in rapid and signiﬁcant antidepressant
effects in patients with treatment-refractory
MDD patients within 2 hours, an effect
that remained signiﬁcant for 7 days.5
However, the clinical application of keta-
mine might be limited by its propensity
to cause psychotomimetic effects of
ketamine.6
The NMDA receptors are tetrameric
proteins composed of 2 NR1 subunits and
2 NR2 subunits, and 4 different NR2
subunits (NR2A-D) exist in the brain. The
NR2B subunit of NMDA receptors is
localized primary in the forebrain includ-
ing the hippocampus, a region implicated
in the pathophysiology of MDD. The
NR2B subunitYselective NMDA receptor
antagonist CP-101,606 is distinct from
that of ketamine, an open-channel blocker
of NMDA receptor. Together, it is likely
that the NR2B subtype NMDA receptor
antagonists, which do not cause psychoto-
mimetic effects, would be better than those
of open-channel blockers (eg, ketamine)
of NMDA receptor. CP-101,606 is a
derivative of prototypical NR2B subunit-
selective drug ifenprodil. We and other
group reported that ifenprodil and its
derivative CP-101,606 had high to moder-
ate afﬁnity at endoplasmic reticulum pro-
tein sigma-1 receptors in the brain7,8; which
play a role in the pathophysiology of
MDD and in the mechanism of anti-
depressants.9Y11 Therefore, the role of
sigma-1 receptors in the mechanism of
action of CP-101,606 should be taken into
consideration. In the future, it may also be
of great interest to study whether or not the
selective sigma-1 receptor agonists cause
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